Clinical trials assessing the treatment of depression increasingly can capitalize on highly accessible smartphone applications to support and facilitate engagement and seamless trial data capture. However, there is one problem: increasing dropout rates evidence low...
Depression
Category
Stanford Researchers & Collaborators Develop SELSER to Identify Brain Wave Signatures to Predict SSRI Response
The National Institutes of Mental Health (NIMH), part of the National Institutes of Health (NIH), have funded research that has led to the discovery of a neural signature predicting whether individuals with depression could likely benefit from sertraline, a commonly...
Emory University to Participate in COMPASS Pathways Psilocybin Clinical Trial Addressing Depression
Emory University investigators are exploring the use of psychedelic drugs as a potential therapy for major depressive disorder. According to a recent local news broadcast, a local woman has seen her life turnaround that’s to the controversial intervention. WSBTV...
UT Southwestern Study Evidences AI-enabled Brain Scan can Improve Depression Diagnosis
Artificial Intelligence (AI) may increasingly determine which course of treatment is best for patients struggling with depression as well as apart of a new generation of “biology-based, objective strategies” to treat psychiatric disorders. UT Southwestern recently...
NYU Langone Study Reveals Psilocybin Dose & Therapy Reduces Anxiety & Depression in Cancer Patients
Stress, anxiety and depression easily mounts with a cancer diagnosis. The fears, uncertainties, and doubts can reign supreme, making cancer patients feel debilitated. Clinical sponsors are increasingly looking to what have traditionally been taboo substances to...
University of Michigan Awarded $6.7m to Study how Social Determinants of Health Impacts Brain Development
The National Institute of Mental Health awarded a $6.7 million grant to the University of Michigan as part the RDoC Initiative—the Research Domain Criteria Initiative—which uses neuroscience and behavioral science to better understand the structure of mental disorders...
Magic Mushroom Based Medication in Trials for Major Depressive Disorder
Psilocybin, the active ingredient in magic mushrooms is being fast-tracked by the FDA for the second time in just over a year. Designated as “Breakthrough Therapy,” the FDA believes that this compound shows strong preliminary evidence in treating depression. ...
Washington University Taylor Family Institute for Innovative Psychiatric Research-Originated Drug in Clinical Trials for Major Depression
33% of 14 million American’s suffering from clinical depression get no relief from today’s approved antidepressant drugs. A new treatment approach involving neurosteroids is on the horizon however that may be more effective. The strategy of using neurosteroids was...
Dynamic University of Rio Grande do Norte Investigator Headed to University of Auckland to Discuss Research into Ayahuasca for Antidepressant Properties
Ayahuasca, an Amazonia indigenous culture psychedelic brew has been used for centuries in traditional spiritual medicine. It will now be the topic of a research-based discussion between Brazil’s University of Rio Grande do Norte and the University of Auckland in New...
Privately-Held Segal Trials Supports Usona Institute’s PSIL201 Clinical Trial Testing the Use of Psilocybin for Major Depression
Segal Trials, a privately held network of research sites throughout South Florida and South Carolina conducting Phase I-IV clinical trials, has been named one of seven sites to initiate a Phase II study of psilocybin—a psychedelic prodrug compound—for major depressive...
Janssen Submits sNDA for Spravato CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder and Active Suicidal Ideation with Intent
Janssen announced the submission of a supplemental New Drug Application (sNDA) to the U.S. FDA seeking a new indication for Spravato (esketamine) CIII nasal spray for the rapid reduction of depressive symptoms in adult patients with major depressive disorder (MDD) who...
Linköping-Led International Team Conclude Antidepressants Safe based on Analysis of 45 Meta-Analyses Combining Many Studies
An International study team concluded antidepressants are generally safe based on an analysis of 45 meta-analyses covering the combined results from many studies. The researchers found no strong evidence of adverse health outcomes associated with antidepressant use....
University of Iowa Hospitals and Clinics Study Use of Transcranial Magnetic Stimulation on Brain Disorders such as Autism & Bipolar
The University of Iowa Hospitals and Clinics (UIHC) is now conducting a clinical trial focusing on the brain with the hope that the study could uncover a treatment for certain brain disorders. Called transcranial magnetic stimulation (TMS), the investigational...
Center for Psychedelic Research Opens at Johns Hopkins Medicine
Johns Hopkins has opened The Center for Psychedelic and Consciousness Research in the nation’s first-ever research center to study the use of psychedelic substances as medicine for a range of mental health ailments, including addiction, depression, and PTSD. With $17...
Massachusetts General Hospital Reports on Study Focusing on Early Stage Alzheimer’s Disease Patients
Massachusetts General Hospital (MGH) recently published a study focusing on preclinical stage of Alzheimer’s disease, a stage when no or minimal symptoms and when interventions might have the potential to prevent the future decline of older adults. MGH finds that...
Flanders University SAVE Trial Finds CPAP Treatment Leads to Decreased Depression
Flanders University researchers have found in the Sleep Apnea Cardiovascular Endpoints (SAVE) trial that a CPAP treatment leads to a decrease in depression cases with cardiovascular patients. Led in Australia, the largest trial of its type and one of a few with this...
ICER Final Report on Spravato Puts in the ‘Low Value for Money’ Category for the Depression Drug
Janssen (J&J) Esketamine recently was approved as an antidepressant by the FDA. Called Spravato, the original cat tranquilizer was used for off-label treatment of severe depression. ICER determined that a fair and rational price for the anti-depression drug is...
FDA Overlooks Red Flags in Janssen’s New Depression Medicine and Approve Anyway
Spravato maker Janssen provided the FDA modest evidence that it worked and only in limited trials. It presented no information about the use of Spravato beyond 60 weeks. Why? Key takeaways published originally by Kaiser Health News and picked up by HealthLeaders...
NIH IGNITE Phase II: $42 Million Infused into Genomic Medicine Interventions
The National Institutes of Health (NIH) moves into phase II of Implementing Genomics in Practice Network (IGNITE)--$42 million will be invested into genomic medicine clinical trial. With a goal of understanding the benefits, applicability and efficacy of genomic...
Emory University Theory: Have We Become an Inflamed, Depressed Nation?
Emory University researchers have produced a research paper theorizing that a powerful connection between dopamine, effort and inflammatory response represents a dynamic systematic mechanism to support the human body to conserve energy. Published in Trends in...